Press releases

23
May 2022
20:30 E.S.T.

Cellectis’ Annual Shareholders’ General Meeting to be Held on June 28, 2022

Read more
16
May 2022
12:30 E.S.T.

Cellectis Presents Research Data on a Novel Immune-Evasive Universal CAR T-cell at ASGCT

Read more
12
May 2022
20:30 E.S.T.

Cellectis Provides Business Update and Reports Financial Results for First Quarter 2022

Read more
5
May 2022
20:30 E.S.T.

Cellectis to Report First Quarter 2022 Financial Results

Read more
5
May 2022
20:00 E.S.T.

Calyxt, Inc., Cellectis’ Majority-Owned Subsidiary, Reports Its First Quarter 2022 Financial Results

Read more
28
Apr 2022
12:00 E.S.T.

Cellectis Publishes Two Articles in Nature Communications Providing Strong Preclinical Validation of UCART123 to Treat AML and BPDCN

Read more
27
Apr 2022
08:00 E.S.T.

Cellectis Receives $20 Million Convertible Note Under Collaboration Agreement with its Partner Cytovia Therapeutics

Read more
8
Apr 2022
20:30 E.S.T.

Cellectis Presents Preclinical Data from its First Allogeneic Dual CAR T-cell Product Candidate UCART20x22 for Patients with Relapsed or Refractory Non-Hodgkin Lymphoma at the American Association for Cancer Research (AACR) 2022 Annual Meeting

Read more
11
Mar 2022
18:15 E.S.T.

Cellectis to Participate in Two Upcoming Investor Conferences in March

Read more
3
Mar 2022
18:46 E.S.T.

Cellectis Provides Business Update and Reports 4th Quarter and Full Year 2021 Financial Results

Read more

Press contacts

For more information on any story, or for press enquiries, get in touch with our communication team

CONTACT US